美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Loxo Oncology

234.66

0.0000

成交量：- -

成交額：- -

市值：72.17億

市盈率：-112.40

高：234.66

開：234.66

低：234.66

收：234.66

52周最高：234.93

52周最低：103.50

股本：3,075.46萬

流通股本：2,752.00萬

量比：- -

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):-2.0877

每股收益(LYR):-5.3102

淨資產收益率：--

總資產收益率：--

市淨率：19.03

市盈率(LYR):-44.19

資料載入中...

總覽公司新聞資訊公告

公司資料

公司名字：

Loxo Oncology

交易所：

NASDAQ

成立時間：

- -

員工人數：

- -

公司地址：

- -

官網：

http://www.loxooncology.com

郵編：

- -

電話：

- -

傳真：

- -

簡介：

Loxo Oncology, Inc.於2013年5月9號在特拉華州成立。公司開發有針對性的基因定義的患者群體的治療癌症的小分子療法。公司的開發方式轉換了相關癌症轉換成藥物，這些藥物能夠有效的和高選擇性的達到關鍵科學見解的預期目標。這些藥物通常能夠達到更高的目標任務和改善相關腫瘤的反應。公司識別和優先考慮的目標有兩種方式。首先，該公司使用的臨床試驗數據來評估藥物的發展，響應信號和識別那些承諾也證明藥物的具體限制，如吸收差，差的分佈或有害的副作用。第二，該公司評估學術研究發現新的目標與新興的驗證。一旦確定目標,公司使用先進的第三方技術來開發候選產品旨在增強目標接觸和特異性。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/LOXO/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"LOXO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LOXO\",,,,,undefined,":{"symbol":"LOXO","market":"US","secType":"STK","nameCN":"Loxo Oncology","latestPrice":234.66,"timestamp":1557432000000,"preClose":234.66,"halted":3,"volume":0,"delay":0,"changeRate":0,"floatShares":27520039,"shares":30754634,"eps":-2.087713,"marketStatus":"停牌","change":0,"latestTime":"05-09 16:00:00 EDT","open":234.66,"high":234.66,"low":234.66,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.087713,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1774252800000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1406865600000,"exchange":"NASDAQ","adjPreClose":234.66,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LOXO\",,,,,undefined,":{"symbol":"LOXO","floatShares":27520039,"roa":"--","roe":"--","lyrEps":-5.31023,"shares":30754634,"dividePrice":0,"high":234.66,"amplitude":0,"preClose":234.66,"low":234.66,"week52Low":103.5,"pbRate":"19.03","week52High":234.93,"institutionHeld":0,"latestPrice":234.66,"eps":-2.087713,"divideRate":0,"volume":0,"delay":0,"ttmEps":-2.087713,"open":234.66,"prevYearClose":234.66},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LOXO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2018-11-08","symbol":"LOXO","fiscalQuarterEnding":"2018/09","expectedEps":-0.07,"name":null,"time":"盤前","type":"earning","dateTimestamp":1541653200000,"reportTimeType":"pre","actualEps":-2.26},{"market":"US","date":"2018-08-09","symbol":"LOXO","fiscalQuarterEnding":"2018/06","expectedEps":-0.54,"name":null,"time":"盤前","type":"earning","dateTimestamp":1533787200000,"reportTimeType":"pre","actualEps":-0.39},{"market":"US","date":"2018-05-08","symbol":"LOXO","fiscalQuarterEnding":"2018/03","expectedEps":-0.6,"name":null,"time":"盤前","type":"earning","dateTimestamp":1525752000000,"reportTimeType":"pre","actualEps":-0.12},{"market":"US","date":"2018-03-01","symbol":"LOXO","fiscalQuarterEnding":"2017/12","expectedEps":-1.22,"name":null,"time":"盤前","type":"earning","dateTimestamp":1519880400000,"reportTimeType":"pre","actualEps":-0.69},{"market":"US","date":"2017-11-02","symbol":"LOXO","fiscalQuarterEnding":"2017/09","expectedEps":-1.38,"name":null,"time":"盤前","type":"earning","dateTimestamp":1509595200000,"reportTimeType":"pre","actualEps":-1.12}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LOXO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LOXO\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.loxooncology.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0207},{"period":"1month","weight":-0.055},{"period":"3month","weight":-0.047},{"period":"6month","weight":-0.0228},{"period":"1year","weight":0.1469},{"period":"ytd","weight":-0.0489}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Loxo Oncology, Inc.於2013年5月9號在特拉華州成立。公司開發有針對性的基因定義的患者群體的治療癌症的小分子療法。公司的開發方式轉換了相關癌症轉換成藥物，這些藥物能夠有效的和高選擇性的達到關鍵科學見解的預期目標。這些藥物通常能夠達到更高的目標任務和改善相關腫瘤的反應。 公司識別和優先考慮的目標有兩種方式。首先，該公司使用的臨床試驗數據來評估藥物的發展，響應信號和識別那些承諾也證明藥物的具體限制，如吸收差，差的分佈或有害的副作用。第二，該公司評估學術研究發現新的目標與新興的驗證。一旦確定目標,公司使用先進的第三方技術來開發候選產品旨在增強目標接觸和特異性。","exchange":"NASDAQ","name":"Loxo Oncology","nameEN":"Loxo Oncology"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"LOXO\",market:\"US\",,,undefined,":null}}